Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annie Fang

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Journal of Clinical Pharmacology|September 8, 2018
No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected SubjectsManoli Vourvahis, Lynn McFadyen, Sunil Nepal, et al.
The Pediatric Infectious Disease Journal|October 13, 2017
Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1Carlo Giaquinto, Muthuhadini Patience Mawela, Kulkanya Chokephaibulkit, et al.
Blood|October 23, 2023
Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta studyAndrew D Leavitt, Barbara A Konkle, Kimo C Stine, et al.
The New England Journal of Medicine|September 25, 2024
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia BAdam Cuker, Kaan Kavakli, Laurent Frenzel, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Journal of Clinical Pharmacology|September 8, 2018
No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected SubjectsManoli Vourvahis, Lynn McFadyen, Sunil Nepal, et al.
The Pediatric Infectious Disease Journal|October 13, 2017
Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1Carlo Giaquinto, Muthuhadini Patience Mawela, Kulkanya Chokephaibulkit, et al.
Blood|October 23, 2023
Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta studyAndrew D Leavitt, Barbara A Konkle, Kimo C Stine, et al.
The New England Journal of Medicine|September 25, 2024
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia BAdam Cuker, Kaan Kavakli, Laurent Frenzel, et al.
Pageof 2